购物车
- 全部删除
- 您的购物车当前为空
NFATc1-IN-1(亦称为compound A04)是通过抑制RANKL诱导的成骨细胞形成的高效抑制剂,其IC50为1.57 μM。它通过减少RANKL诱导的NFATc1核内转移来发挥抗成骨细胞生成效应。由于其显著的特性,NFATc1-IN-1对于推进与骨质疏松症相关研究具有重要潜力[1]。
为众多的药物研发团队赋能,
让新药发现更简单!
NFATc1-IN-1(亦称为compound A04)是通过抑制RANKL诱导的成骨细胞形成的高效抑制剂,其IC50为1.57 μM。它通过减少RANKL诱导的NFATc1核内转移来发挥抗成骨细胞生成效应。由于其显著的特性,NFATc1-IN-1对于推进与骨质疏松症相关研究具有重要潜力[1]。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 213 | 现货 | |
5 mg | ¥ 467 | 现货 | |
10 mg | ¥ 821 | 现货 | |
25 mg | ¥ 1,660 | 现货 | |
50 mg | ¥ 2,490 | 现货 | |
100 mg | ¥ 3,730 | 现货 | |
500 mg | ¥ 7,880 | 现货 |
产品描述 | NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1]. |
靶点活性 | Osteoclast:1.57 μM |
体外活性 | NFATc1-IN-1(0、0.5、1.0、1.5、2.0、2.5 μM,4天)在抑制破骨细胞形成和功能方面表现出强大活性,从而导致骨吸收减少,同时在高达2.5 μM的浓度下对破骨细胞前体细胞没有表现出细胞毒性效应。NFATc1-IN-1(1.5-2.5 μM,24小时)阻断NFATc1核内转移并降低NFATc1水平。 |
分子量 | 375.11 |
分子式 | C13H8F2INO2 |
CAS No. | 1912422-56-0 |
Smiles | C(NC1=C(F)C=C(I)C=C1)(=O)C2=C(O)C=CC(F)=C2 |
存储 | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 112.5 mg/mL (299.9 mM ), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容